Moderna says its coronavirus vaccine shows promising results in small trial of elderly patients

The vaccine was tested on 10 adults between the ages of 56 and 70 and 10 elderly adults aged 71 and older, Moderna said.
Each participant received two 100 microgram doses of the vaccine 28 days apart.
The vaccine produced neutralizing antibodies, which researchers believe are necessary to build immunity to the virus, and killer T-cells, Moderna said.